Lipocine Total Assets 2011-2026 | LPCN

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Lipocine

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
23 M	37.5 M	52.5 M	25.4 M	19.7 M	20.9 M	25.3 M	27.3 M	45.4 M	28 M	46.1 M	577	32.4 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
52.5 M	577	27 M

Quarterly Total Assets Lipocine

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
16.1 M	18.6 M	20.5 M	22.5 M	20.7 M	23 M	-	23 M	24.8 M	30.5 M	34 M	37.5 M	39.4 M	42.2 M	47.6 M	52.5 M	40.4 M	47.2 M	50.6 M	25.4 M	25.4 M	25.4 M	25.4 M	19.7 M	19.7 M	19.7 M	19.7 M	20.9 M	20.9 M	20.9 M	20.9 M	25.3 M	25.3 M	25.3 M	25.3 M	27.3 M	27.3 M	27.3 M	27.3 M	45.4 M	45.4 M	45.4 M	45.4 M	28 M	28 M	28 M	28 M	46.1 M	46.1 M	46.1 M	46.1 M	5.57 M	5.57 M	577	577	32.4 K	32.4 K	32.4 K	32.4 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
52.5 M	577	26.8 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Celldex Therapeutics CLDX	583 M	$ 34.99	3.35 %	$ 2.32 B	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 4.36	9.92 %	$ 10.5 B	Australia
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Citius Pharmaceuticals CTXR	117 M	$ 0.88	2.99 %	$ 5.92 M	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Akari Therapeutics, Plc AKTX	47.9 M	$ 5.52	7.71 %	$ 372 B	Britain
Aligos Therapeutics ALGS	88.5 M	$ 6.66	-13.05 %	$ 65.8 M	USA
Alnylam Pharmaceuticals ALNY	4.97 B	$ 309.33	-3.37 %	$ 40.5 B	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Forte Biosciences FBRX	82.8 M	$ 32.91	4.71 %	$ 426 M	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Galectin Therapeutics GALT	19.5 M	$ 2.47	9.29 %	$ 158 M	USA
Amphastar Pharmaceuticals AMPH	1.63 B	$ 22.62	3.71 %	$ 1.06 B	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
BioNTech SE BNTX	22 B	$ 104.72	2.55 %	$ 27.2 B	Germany
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Galapagos NV GLPG	3.41 B	$ 29.25	1.35 %	$ 2.69 B	Belgium
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Grifols, S.A. GRFS	21.4 B	$ 8.73	1.54 %	$ 6.83 B	Spain
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
GT Biopharma GTBP	8.11 M	$ 0.38	-3.91 %	$ 2.1 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.04	-1.3 %	$ 5 M	Israel
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
BioXcel Therapeutics BTAI	44.9 M	$ 1.19	10.75 %	$ 14.5 M	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Hoth Therapeutics HOTH	7.6 M	$ 0.72	-3.12 %	$ 9.94 M	USA
Akebia Therapeutics AKBA	377 M	$ 1.44	6.65 %	$ 370 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Harmony Biosciences Holdings HRMY	1.27 B	$ 30.25	2.82 %	$ 1.74 B	USA
Aquestive Therapeutics AQST	160 M	$ 4.37	2.58 %	$ 467 M	USA
InflaRx N.V. IFRX	55.2 M	$ 1.56	29.91 %	$ 152 M	Germany
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
Arcutis Biotherapeutics ARQT	433 M	$ 24.77	2.4 %	$ 3.15 B	USA
Burford Capital Limited BUR	3.11 B	$ 4.97	6.32 %	$ 792 M	Britain
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
Immutep Limited IMMP	157 M	$ 0.59	1.79 %	$ 1.08 B	Australia
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Cabaletta Bio CABA	165 M	$ 3.41	-3.12 %	$ 343 M	USA